About CYTOAGENTS INC
CytoAgents is a biotechnology company focused on developing CTO1681, a novel oral immunomodulator targeting inflammatory and oncology indications through the modulation of prostaglandin and prostacyclin pathways. The company aims to provide safer, steroid-sparing treatments for conditions such as pulmonary arterial hypertension, asthma, atopic dermatitis, and CAR-T-related cytokine release syndrome.
Development of CTO1681, a novel oral prostacyclin/prostaglandin analogueModulation of vascular and inflammatory pathways through selective receptor signalingTargeting of cytokine-driven inflammation in oncology and inflammatory diseasesConducting Phase 1b/2a clinical trials for CAR-T-related inflammation and other indications
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to CYTOAGENTS INC right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.